Autor: |
Christiana Graf, Roberta D’Ambrosio, Elisabetta Degasperi, Stefania Paolucci, Jordi Llaneras, Johannes Vermehren, Georg Dultz, Kai-Henrik Peiffer, Fabian Finkelmeier, Eva Herrmann, Stefan Zeuzem, Maria Buti, Pietro Lampertico, Julia Dietz, Christoph Sarrazin |
Jazyk: |
angličtina |
Rok vydání: |
2024 |
Předmět: |
|
Zdroj: |
JHEP Reports, Vol 6, Iss 3, Pp 100994- (2024) |
Druh dokumentu: |
article |
ISSN: |
2589-5559 |
DOI: |
10.1016/j.jhepr.2023.100994 |
Popis: |
Background & Aims: Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed in an integrative analysis of three large real-world cohorts. Methods: Consecutive patients re-treated with VOX/VEL/SOF after DAA failure were enrolled between 2016 and 2021 in Austria, Belgium, Germany, Italy, Spain and Switzerland. Results: A total of 746 patients were included: median age was 56 (16-88) years and 77% were male. Most patients were infected with HCV genotype 1 (56%) and 3 (32%). 86% of patients carried resistance-associated substitutions in the NS3, NS5A or NS5B regions. Overall, 95.4% (683/716) of patients achieved a sustained virologic response. Treatment effectiveness was significantly affected by advanced liver disease (p |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|